ROR1 and B-cell chronic lymphocytic leukemia: Cirmtuzumab, a monoclonal antibody targeting the Wnt receptor ROR1, has shown excellent results in models of chronic lymphocytic leukemia (CLL) and is now in phase I clinical trial (NCY02860676, completed, results submitted but not yet posted).